Printer Friendly
The Free Library
23,375,127 articles and books


Discontinued Drugs in 2005 - Featured Series of Reports From Expert Opinion.

LONDON, October 17 /PRNewswire/ -- The current issue of Expert Opinion on Investigational Drugs features the first in a series of reports by key opinion leaders analysing discontinued drugs in 2005.

Dr Keith Suckling (formerly GlaxoSmithKline, UK) provides his expert opinion on cardiovascular drugs that were dropped from clinical development in 2005; and Professor Lloyd Kelland (Head of Biology, Wolfson Institute for Biomedical Research, University College London) discusses the 20 drugs discontinued in 2005 in the field of oncology.

These will be followed in later issues by papers on pulmonary, dermatological, gastrointestinal and arthritis drugs by Professor Kenneth KC Lee (The Chinese University of Hong Kong); drugs for disorders of the central nervous system by Professor Robert Kerwin (Professor of Clinical Neuropharmacology, Institute of Psychiatry, King's College London); anti-infectives by Dr Nafsika Georgopapadakou (MethylGene); and renal, endocrine and metabolic drugs by Dr Jerry Colca (Kalamazoo Metabolic Research).

The series of papers is introduced by an editorial, featured in the November issue, by Dr Louis A Tartaglia (Senior Vice President and General Manager, Drug Repositioning and Selection, Gene Logic) on the value of drug repositioning.

Data from the Pharmaprojects drug R&D pipeline database estimates around 100 compounds are discontinued every year, at an enormous cost to the pharmaceutical industry. There is clearly a need to identify the reasons for these failures and develop better and more efficient methods to avoid such losses in future.

TARTAGLIA LA: Complementary new approaches enable repositioning of failed drug candidates. Expert Opin. Investig. Drugs (2006) 15(11):1295-1298 doi:10.1517/13543784.15.11.1295 http://www.expertopin.com/doi/abs/10.1517/13543784.15.11.1295

SUCKLING K: Discontinued drugs in 2005: cardiovascular drugs. Expert Opin. Investig. Drugs (2006) 15(11):1299-1308 doi:10.1517/13543784.15.11.1299 http://www.expertopin.com/doi/abs/10.1517/13543784.15.11.1299

KELLAND L: Discontinued drugs in 2005: oncology drugs. Expert Opin. Investig. Drugs (2006) 15(11):1309-1318 doi:10.1517/13543784.15.11.1309 http://www.expertopin.com/doi/abs/10.1517/13543784.15.11.1309

About Expert Opinion

For over a decade, the Expert Opinion series has provided systematic and authoritative reviews to support every stage of the drug discovery and R&D pipeline from target to market. Each of the ten journals in the series covers a specific aspect of the pharmaceutical pipeline.

The series contains the following journals: Expert Opinion on Biological Therapy, Expert Opinion on Drug Delivery, Expert Opinion on Drug Metabolism & Toxicology, Expert Opinion on Drug Safety, Expert Opinion on Emerging Drugs, Expert Opinion on Investigational Drugs, Expert Opinion on Pharmacotherapy, Expert Opinion on Therapeutic Patents, Expert Opinion on Therapeutic Targets and Expert Opinion on Drug Discovery.

 For further information:

 Phil Garner, Publisher
 Telephone: +44-(0)20-7017-6775
 Email: phil.garner@informa.com
 Website: www.expertopin.com



For further information: Phil Garner, Publisher, Telephone: +44-(0)20-7017-6775, Email: phil.garner@informa.com, Website: www.expertopin.com
COPYRIGHT 2006 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Geographic Code:4EUUK
Date:Oct 17, 2006
Words:485
Previous Article:CONSISTEL's In-Building Mark Advances to a Greater Heights.
Next Article:Precision Marketing Techniques Yield High Results in Key Customer-Centric Performance Metrics, According to Aberdeen Group Research.
Topics:



Related Articles
Oseltamivir in the Management of Influenza by John Oxford - Featured Article From Expert Opinion.
Oseltamivir in the Management of Influenza by John Oxford - Featured Article From Expert Opinion.
Facial Transplantation: Adding to the Reconstructive Options After Severe Facial Injury and Disease by Peter Butler - Featured Article From Expert...
Facial Transplantation: Adding to the Reconstructive Options After Severe Facial Injury and Disease by Peter Butler - Featured Article From Expert...
Expert Opinion on Drug Discovery - Harmonising Drug Discovery in the Post-Genomic Era.
Expert Opinion on Drug Discovery - Harmonising Drug Discovery in the Post-Genomic Era.
Discontinued Drugs in 2005 - Featured Series of Reports From Expert Opinion.
In Situ Click Chemistry: a Powerful Means for Lead Discovery by K Barry Sharpless and Roman Manetsch - Featured Article From Expert Opinion.
WHO Introduces the Helminth Drug Initiative With Special Supplement in the Expert Opinion on Drug Discovery.
WHO Introduces the Helminth Drug Initiative With Special Supplement in the Expert Opinion on Drug Discovery.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters